Additional Information

Description

Trulicity 1.5 mg/0.5 mL is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the management of type 2 diabetes mellitus. It enhances glycemic control by stimulating insulin secretion in response to elevated blood glucose levels. The medication also suppresses glucagon secretion, which helps reduce hepatic glucose production. It is not intended for use in patients with type 1 diabetes or diabetic ketoacidosis.

The prefilled, single-dose pens contain dulaglutide, which is administered via subcutaneous injection once weekly. The formulation ensures consistent absorption, providing prolonged glucose control. The pen design facilitates self-administration, reducing the complexity of diabetes management. Trulicity is commonly prescribed in conjunction with diet and exercise to improve blood sugar levels.

Trulicity has demonstrated efficacy in lowering HbA1c levels and promoting weight loss in some patients. The medication may cause gastrointestinal side effects, including nausea, vomiting, and diarrhea, particularly at the start of therapy. Hypoglycemia risk increases when combined with other glucose-lowering agents such as insulin or sulfonylureas.